Tetanus toxoid-derived helper peptide-MHC class II complex (TT-pMHC-II)

The Tetanus toxoid-derived helper peptide presented on MHC class II (TT-pMHC-II) is an antigenic complex consisting of immunodominant CD4+ T-cell epitopes from the tetanus toxin, such as the P2 (QYIKANSKFIGITEL) or P30 (FNNFTVSFWLRVPKVSASHLE) peptides, bound to Major Histocompatibility Complex (MHC) class II molecules [1]. These peptides are recognized as "universal" or "promiscuous" epitopes because they possess a high binding affinity for a wide variety of human leukocyte antigen (HLA) alleles, including various HLA-DR, HLA-DP, and HLA-DQ isoforms, ensuring their presentation in a vast majority of the global population [2]. Because most individuals have been vaccinated against tetanus during childhood, they maintain a robust and long-lasting pool of circulating memory CD4+ T cells specific to these epitopes [3]. In modern immunotherapy, this complex is utilized as a therapeutic target to redirect these pre-existing memory T cells to specific sites, such as the tumor microenvironment. By engineering cells to present these peptides or using bispecific molecules to bridge effector T cells to the TT-pMHC-II complex, researchers aim to harness the potent "helper" signals—such as the secretion of Interferon-gamma and Interleukin-2—to reverse local immunosuppression and enhance the activity of cytotoxic CD8+ T cells [4, 5]. This strategy effectively "tricks" the immune system into mounting a secondary recall response against a target that would otherwise be ignored by the immune system.

Other names

Tetanus toxoid CD4+ T-cell epitopeP2 peptide-MHC II complexP30 peptide-MHC II complexUniversal helper T-cell epitopeTT-derived peptide-HLA-II complexTetanus toxoid promiscuous epitope

Recruitment and activation of pre-existing memory CD4+ T cells to provide local immune help, secrete pro-inflammatory cytokines, and enhance anti-tumor or anti-pathogen activity.